Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies-Reference-Cited by-同舟云学术

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies

Published:2023-01-23 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Nishikubo Masashi,Shimomura Yoshimitsu^ORCID,Yamamoto Ryusuke,Yoshioka Satoshi^ORCID,Maruoka Hayato,Nasu Seiko,Nishioka Tomomi,Sakizono Kenji,Mitsuyuki Satoshi,Kubo Tomoyo,Okada Naoki,Nakagawa Daishi,Kamijo Kimimori,Imoto Hiroharu,Nagai Yuya,Hiramoto Nobuhiro,Yonetani Noboru,Kondo Tadakazu^ORCID,Miyakoshi Chisato^ORCID,Doi Asako,Ishikawa Takayuki

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00792-z.pdf

Reference14 articles.

1. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–e592.

2. Nishikubo M, Shimomura Y, Maruoka H, Nasu S, Nishioka T, Sakizono K, et al. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: an observational study. Br J Haematol. 2022;197:709–13.

3. Centers for Disease Control and Prevention. Stay up to date with COVID-19 vaccines including boosters. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html. Accessed October 2022.

4. Beaton B, Sasson SC, Rankin K, Raedemaeker J, Wong A, Hastak P, et al. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses. Am J Hematol. 2023;98:131–9.

5. Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood 2022;139:678–85.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients;eNeurologicalSci;2024-09

2. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study;Clinical Lymphoma Myeloma and Leukemia;2024-05

3. An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab;Cancer Medicine;2024-02

4. Sequential cellular and humoral responses after repetitive COVID‐19 vaccination in patients treated with anti‐CD20 antibodies;British Journal of Haematology;2023-11-14

5. COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma;Molecular and Clinical Oncology;2023-10-18